Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.
Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.
The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 22 Strathmore Rd,
- Industry
- Biotechnology
- Website
- https://www.avengebio.com
- HQ
- Natick, Massachusetts
Avenge Bio Questions
Avenge Bio's website is https://www.avengebio.com
Avenge Bio's LinkedIn profile is https://www.linkedin.com/company/avenge-bio
Avenge Bio has
2 employees.
View email and phone details for 2
employees at Avenge Bio.
Avenge Bio's industry is
Biotechnology
Avenge Bio's top competitors are
Korro Bio, Inc.,
Verve Therapeutics,
Avalyn Pharma,
Intellia Therapeutics, Inc.,
Beam Therapeutics,
Wave Life Sciences,
Entrada Therapeutics,
Sarepta Therapeutics,
Tessera Therapeutics,
Voyager Therapeutics, Inc..
Avenge Bio's categories are Biotechnology
Avenge Bio's founding year is 2019
